<DOC>
	<DOCNO>NCT02973321</DOCNO>
	<brief_summary>Primary Objective : The primary objective study ass dose-response relationship SAR425899 versus placebo term glycemic control measure change glycosylated hemoglobin ( HbA1c ) . Secondary Objectives : - To assess effect SAR425899 body weight . - To assess safety immunogenicity profile SAR425899 , include assessment heart rate ( HR ) change electrocardiogram ( ECG ) Holter monitor . - To assess proportion patient achieve predefined HbA1c target &lt; 7 % &lt; 6.5 % well proportion patient achieve ≥5 % ≥10 % body weight loss . - To assess effect daily dose SAR425899 additional parameter glycemic control lipid metabolism . - To assess effect daily dose SAR425899 additional pharmacodynamic ( PD ) biomarkers . - To assess pharmacokinetic ( PK ) profile parameter SAR425899 , inter-individual inter-occasion variability PK parameter use population PK approach .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy SAR425899 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The total study duration approximately 30 week , consist 3 week screen period site , 26 week treatment period , 3 day post treatment follow period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Inclusion criterion : Patients type2 diabetes mellitus ( T2DM ) least 3 month screen visit . On diet/exercise and/or treatment metformin ( stable dose ≥1500 mg/day maximal tolerate dose ) least 3 month prior screen . Signed informed consent . Exclusion criterion : At screen , patient 's age &lt; legal age adulthood &gt; 80 year . Glycated hemoglobin screen visit &lt; 7.0 % &gt; 10.0 % . Body mass index ( BMI ) &lt; 25 kg/m^2 &gt; 45.0 kg/m^2 . Pregnant lactating woman . Women childbearing potential ( WOCBP ) protect highlyeffective method ( ) birth control and/or unwilling unable test pregnancy . Diagnosis type 1 diabetes mellitus . Fasting plasma glucose &gt; 15 mmol/L ( 270 mg/dL ) measure central laboratory screening ( Visit 1 ) , confirm ( &gt; 15 mmol/L [ 270 mg/dL ] ) repeat test randomization . Treatment glucoselowering agent ( ) metformin , currently within 3 month prior screen . Previous insulin use , except episode ( ) shortterm treatment ( ≤15 consecutive day ) intercurrent illness pregnancy , use insulin within last 6 month . Contraindication ( ) metformin use . Contraindication ( ) liraglutide use . Significant change body weight 3 month screen . Poorly control hypertension ( rest systolic blood pressure ( SBP ) &gt; 160 mm Hg and/or diastolic blood pressure ( DBP ) &gt; 95 mm Hg screening ) . History long QT syndrome and/or QTc 450 m screen visit . History pancreatitis pancreatectomy . History weight loss surgery . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC . Any prior exposure drug belong class glucagonlike peptide1 ( GLP1 ) receptor agonists/GLP1 analog . Contraindications know hypersensitivity reaction glucagon . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>